Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography
about
Predicting the Response of Neoadjuvant Therapy for Patients with Esophageal Carcinoma: an In-depth Literature ReviewPrognostic significance of (18)FDG PET/CT in colorectal cancer patients with liver metastases: a meta-analysisThe predictive value of 18F-FDG PET for pathological response of primary tumor in patients with esophageal cancer during or after neoadjuvant chemoradiotherapy: a meta-analysis.Visualization, imaging and new preclinical diagnostics in radiation oncology.NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial).Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST.Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.Relationship between the Temporal Changes in Positron-Emission-Tomography-Imaging-Based Textural Features and Pathologic Response and Survival in Esophageal Cancer Patients.Positron Emission Tomography (PET) in OncologyFrom RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.18F-FDG PET/CT imaging in oncologyPositron emission tomography in cancer research and treatment.18F-Fluoro-2-deoxyglucose positron emission tomography in the evaluation of gastrointestinal malignancies.The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinomaShould preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients?Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation.18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.PET/CT and hepatic radiation injury in esophageal cancer patients.Positron emission tomography: clinical applications in oncology. Part 1.The contribution of PET/CT to improved patient management.Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.Role of positron emission tomography in the (re-)staging of oesophageal cancer.(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response.Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.Functional PET imaging in cancer drug development.Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma.PET/CT in oncology: for which tumours is it the reference standard?The role of positron emission tomography in esophageal cancer.The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer.Clinical usefulness of 18F-FDG PET/CT in the restaging of esophageal cancer after surgical resection and radiotherapyChemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.Role of barium esophagography in patients with locally advanced esophageal cancer: evaluation of response to neoadjuvant chemoradiotherapy.PET imaging for Treatment Response in CancerTiming and intensity of changes in FDG uptake with symptomatic esophagitis during radiotherapy or chemo-radiotherapy.Role and cost effectiveness of PET/CT in management of patients with cancer.Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis.Endoscopic management of esophageal cancer after definitive chemoradiotherapy.
P2860
Q26777898-AC051975-D1A4-47F2-9B17-189EA5074B4EQ28081159-87EAC0D7-C101-4184-84F4-33CBA16F20F6Q30393722-664CD332-2F7C-4FC6-A8F4-C5B5A7E3E214Q30725740-D9C42C53-F27E-4786-8797-DBFD9CFC73B3Q33356751-2BFF575B-D249-41CB-A05C-8751D9D2042EQ34023973-948748E2-F060-42B0-81C3-00F36578E5F2Q34104159-EC345CFB-A982-4930-A712-A18E0C6F1B6BQ34298027-78917049-B331-4AE8-BCBD-101871F7F310Q34390923-A9BD65CC-F01D-4D31-8944-5A73A70A5DB3Q34521659-BF6B15DE-F8B7-4E9E-B45B-5EDCD59B0DC0Q34774840-FC6D0762-FD65-4468-8EF4-27CD68C1ADE5Q34978457-F757E777-6B96-4428-AA09-75D1FCA96DFDQ35006097-487A7ABE-CF0D-467E-8708-36269910DE55Q35081118-EFD109B7-1462-4572-97C3-52013DFB0C8AQ35127213-09CB07D5-ADE0-4141-B1AB-0B15330E2547Q35769322-30275166-57FB-45A4-9DE9-865C95D43233Q35824736-4777AECE-C091-4481-A6E0-E5C635E22B7EQ36022348-51119BAA-CDB3-40CA-88A4-3B271DCFED56Q36201687-79A95264-6E35-414E-A52F-4D7D7A8F2DCDQ36295210-77E8FF8D-0BD0-40FE-8689-C7E2EFBF122BQ36334917-CD24C81C-BF51-4F9C-BA91-6CED1A44B155Q36371912-FF9B6195-AA06-4CF7-91B4-6DC2DCDE1AC0Q36427789-372B2E3B-5730-4FB4-83E6-EFB2FFA7D535Q36510702-9B487648-9FB1-4064-8767-66053E54F768Q36611842-C1286B9D-39E4-4AAC-BDE2-5C85D19BB41EQ36626093-14867157-FDA7-417D-AE14-043C0EBDB900Q36768305-43B1BC65-9847-48DD-8884-D5E0B42CF54DQ36775121-6D866CEB-C3E6-43EC-9089-3D680FF725F1Q36963748-A99AD55E-47BF-4C32-8F07-02180E46633DQ37072481-95D6ED9C-0D21-4729-8C2D-70E18F76C7A1Q37076617-8B8A4282-B522-41FF-A23D-63EC2DA3B9AFQ37161611-189B74B3-AC79-4CBE-AB26-F5C087D23224Q37342399-AFF27521-06CB-4E79-8298-F907AE3FE548Q37348247-ED4DD5E7-D979-4455-99D2-4C7A08BFC8DDQ37402817-B2ACDC51-20A5-43EB-99E6-F3EB8743E2F5Q37465205-5F83EF94-5845-4C51-8E38-CF2099447445Q37717566-807A19AE-4B39-4E9B-A850-7EB9C6C9EB0CQ37768682-F8D5DE39-9FEC-4584-8DF1-0A1256D27D5EQ37984273-3AE402AC-35E2-4461-AE60-30A9AC8C2627Q38074582-A1415D4D-D35F-44D8-AEAA-B5315385FC69
P2860
Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Neoadjuvant therapy of esophag ...... y positron emission tomography
@ast
Neoadjuvant therapy of esophag ...... y positron emission tomography
@en
Neoadjuvant therapy of esophag ...... y positron emission tomography
@nl
type
label
Neoadjuvant therapy of esophag ...... y positron emission tomography
@ast
Neoadjuvant therapy of esophag ...... y positron emission tomography
@en
Neoadjuvant therapy of esophag ...... y positron emission tomography
@nl
prefLabel
Neoadjuvant therapy of esophag ...... y positron emission tomography
@ast
Neoadjuvant therapy of esophag ...... y positron emission tomography
@en
Neoadjuvant therapy of esophag ...... y positron emission tomography
@nl
P2093
P2860
P3181
P1433
P1476
Neoadjuvant therapy of esophag ...... y positron emission tomography
@en
P2093
F Zimmerman
J R Siewert
M Schwaiger
P2860
P3181
P356
10.1097/00000658-200103000-00002
P407
P577
2001-03-01T00:00:00Z